Chemours CompanyCC
Price$13.48

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $5.8B+0.2% YoYTTM through 30 Jun 2026
Net Income -$304M-540.6% YoYTTM through 30 Jun 2026
Free Cash Flow $218MTTM through 30 Jun 2026

Margins

Current
Gross Margin15.4%
EBITDA Margin4.6%
Operating Margin-0.9%
Net Margin-5.2%

Returns

-4.3%ROA

Balance Sheet Health

Debt / Equity19.36x
Current Ratio1.78x
Net Debt$3.6B
Cash & Equivalents$671M

Quality Metrics

Altman Z-Score1.36
Piotroski F-Score4 / 9
FCF Margin3.8%
Rule of 406.0
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $5.8B
Diluted EPS-$2.00TTM
'19'20'21'22'23'24'25
FY2025: $-2.57

Dividend

$0.18Per share, FY20261.17%Yield-29.4%5-yr growth

Capital Allocation

R&D Spend$106M
Capex Intensity3.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.